The Hilden, Germany, company on Tuesday said its rapid portable test could detect SARS-CoV-2 - the virus that causes covid-19 - "antigens in people with active infections in less than 15 minutes and process on average around 30 swab samples per hour."
An antigen is a substance that causes the immune system to produce antibodies against it.
The Access Anti-SARS-CoV-2 Antigen Test will be launched in partnership with Australian digital diagnostics firm Ellume. In August, Qiagen first launched a similar test for coronavirus with Ellume.
Qiagen will apply for U.S. Food and Drug Administration's emergency-use authorization and seek CE-IVD registration in Europe to launch two versions of the test - one for labs and one for point-of-care.
“The Access Antigen Test is fast, easy to use and cost-effective and will be a valuable tool to address the so far unmet high-volume testing needs for SARS-CoV-2 antigens in situations where time is of the essence,” said Thierry Bernard, chief executive of Qiagen.
At last check Qiagen shares were 2.4% higher at $49.41.
The trial was halted after “a suspected serious adverse reaction in a participant" in the U.K., Stat reported. AstraZeneca is developing the vaccine candidate with the University of Oxford.
At last check AstraZeneca American depositary receipts were trading down 1.5% at $53.90.